Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Jan 13, 2021 2:42pm
193 Views
Post# 32286680

RE:RE:RE:SPCEO1 on the sell side now ?

RE:RE:RE:SPCEO1 on the sell side now ?While many here are big fan of Tanguy I am absolutely not. yes he closed the deal for the cancer which was at the time at best a lottery ticket with high price tag now it looks like a more legit investment but it could have gone the other way and still can.
He was the guy projecting 5 to10 times Trogarzo sales vs Egrifta well 3 years into commercialization of the drug we know now it is not going to come even close to those estimates and Mr T and his team early into the process realized that but failed to inform the market, we saw the SP declining Q after Q until
more than a year later they eventually adjusted their estimates and SP got beat badly, if they had made that adjustment earlier the SP would get hit once from double digits and would settle down at higher levels also they lost tone of credibility by holding back on bad news.
I am much more comfortable with Paul being upfront for instance he decided to issue a profit warning last quarter and made necessary changes to reverse it and yes it paid off. I was hoping he would replace some of the upper management team with more competent folks by now but maybe the pandemic is restraining him from doing that. I believe Paul is the most competent person in this company surrounded by....


FredTheVoice wrote: Should we call back TANGUAY ?

Lets see, I am not as negative and emotive about it all..........I think the board lost it here.......

We will all know pretty soon who's right......

FTV.


<< Previous
Bullboard Posts
Next >>